The Wire · All news

GLP-1 drugs, sight loss and possible claims

Harvard study in JAMA Ophthalmology links semaglutide to NAION

Published Updated

By People's Justice

What happened

A Harvard Medical School team publishes a study in JAMA Ophthalmology reporting that patients prescribed semaglutide had a substantially higher risk of NAION — a hazard ratio of 4.28 among people with type 2 diabetes and 7.64 among overweight or obese patients. The authors note the study is observational and call for further research.

Event date:

Source: pubmed.ncbi.nlm.nih.gov

Related news

  1. GLP-1 drugs, sight loss and possible claims

    JPML creates the GLP-1 vision-loss MDL — No. 3163

    The U.S. Judicial Panel on Multidistrict Litigation creates In re GLP-1 RAs NAION Products Liability Litigation, MDL No. 3163, in the Eastern District of Pennsylvania before Judge Karen Marston, keeping the vision-loss claims separate from an earlier GLP-1 gastrointestinal-injury litigation.

    Source: jpml.uscourts.gov